Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lunresertib - Debiopharm

Next Previous
Drug Profile

Lunresertib - Debiopharm

Alternative Names: CCNE1-SL inhibitor - Repare Therapeutics; Debio-2513; Lunre; Manchester; RP-6306

Latest Information Update: 23 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Repare Therapeutics
  • Developer Canadian Cancer Trials Group; Debiopharm; Repare Therapeutics; University Health Network
  • Class Amides; Antineoplastics; Pyridines; Small molecules
  • Mechanism of Action PKMYT1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I Ovarian cancer; Uterine cancer

Most Recent Events

  • 16 Apr 2026 Phase-I development is ongoing in Solid-tumours(In adolescents, In the elderly, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater, In adults) in USA and Canada (PO) (NCT04855656)
  • 05 Feb 2026 Canadian Cancer Trials Group completes a phase-II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable, Recurrent) in Canada (PO) (NCT05605509)
  • 28 Jan 2026 Repare Therapeutics has been acquired by XenoTherapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top